( MENAFN - PR Newswire) Kidney Cancer Research Aims to Enhance Metastatic Patient Management by Pinpointing Biomarker to Optimize Clinical Decision-Making BINYAMINA, Israel and CARY, N.C., June 2, 2024 /PRNewswire/ -- OncoHost , a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a research study with Dana-Farber Cancer Institute, a world leader in adult and pediatric cancer treatment and research, to identify biomarkers for renal cell carcinoma (RCC), a type of kidney cancer.
Immune-checkpoint inhibitor (ICI) therapy has transformed treatment outcomes for RCC. However, ICIs can also trigger immune-related adverse events and may not benefit all patients. "We are excited to collaborate with Dana-Farber Cancer Institute on this important research study," said Ofer Sharon, MD, CEO of OncoHost.
"As we enter the era of precision medicine, validated biomarkers are increasingly used to guide treatment decisions and uncover resistance pathways in various types of tumors. However, RCC lacks reliable biomarkers to predict ICI response. Our goal is to overcome this challenge to improve clinical decision-making in the first line setting and, ultimately, patient outcomes.
" The collaboration will leverage Dana-Farber's repository of patient plasma samples and corresponding clinical data, providing essential materials for OncoHost to create a proteomic plasma profile. "Patients with renal cell carcinoma currently do not have an.
